Dr. Tara O'Donohue, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Expert in Uterine Tumors
Studies Cancer
13 reported clinical trials
22 drugs studied
Area of expertise
1Uterine Tumors
Global LeaderNTRK positive
Stage IV
ALK positive
2Cancer
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Tara O'Donohue, MD is currently running
Repotrectinib
for Solid Tumors in Young Patients
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Recruiting1 award Phase 1 & 214 criteria
Repotrectinib + Chemotherapy
for Cancer
This trial tests the safety and effectiveness of repotrectinib combined with chemotherapy in children and young adults with severe, spreading cancer. The goal is to find the best dose with few side effects and see if it works well to stop cancer growth.
Recruiting1 award Phase 1 & 2
More about Tara O'Donohue, MD
Clinical Trial Related7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Tara O'Donohue, MD has experience with
- Repotrectinib
- Larotrectinib
- Selpercatinib
- Tipifarnib
- Irinotecan And Temozolomide
- Neratinib
Breakdown of trials Tara O'Donohue, MD has run
Uterine Tumors
Cancer
Brain Tumor
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tara O'Donohue, MD specialize in?
Tara O'Donohue, MD focuses on Uterine Tumors and Cancer. In particular, much of their work with Uterine Tumors has involved NTRK positive patients, or patients who are Stage IV.
Is Tara O'Donohue, MD currently recruiting for clinical trials?
Yes, Tara O'Donohue, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Tara O'Donohue, MD has studied deeply?
Yes, Tara O'Donohue, MD has studied treatments such as Repotrectinib, Larotrectinib, Selpercatinib.
What is the best way to schedule an appointment with Tara O'Donohue, MD?
Apply for one of the trials that Tara O'Donohue, MD is conducting.
What is the office address of Tara O'Donohue, MD?
The office of Tara O'Donohue, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.